Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 14/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038876 | 1.00 | HSD17B3 (0.53) | HSD17B3NOTUMCYP11B1CYP11B2RECQL | |
| SCHEMBL5046218 | 0.92 | HSD17B3 (0.43) | HSD17B3NOTUMCYP11B1CYP11B2 | |
| SCHEMBL5046212 | 0.92 | HSD17B3 (0.43) | HSD17B3NOTUMCYP11B1CYP11B2 | |
| SCHEMBL6387449 | 0.89 | HSD17B3 (0.56) | HSD17B3NOTUMCYP11B1CYP11B2 | |
| SCHEMBL6387452 | 0.89 | HSD17B3 (0.56) | HSD17B3NOTUMCYP11B1CYP11B2 | |
| SCHEMBL5043772 | 0.87 | HSD17B3 (0.42) | HSD17B3CYP11B1CYP11B2 | |
| SCHEMBL5043770 | 0.87 | HSD17B3 (0.42) | HSD17B3CYP11B1CYP11B2 | |
| SCHEMBL5042909 | 0.86 | HSD17B3 (0.50) | HSD17B3NOTUM | |
| SCHEMBL5042904 | 0.86 | HSD17B3 (0.50) | HSD17B3NOTUM | |
| SCHEMBL15063045 | 0.85 | HSD17B3 (0.52) | HSD17B3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725565-B1 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B1, HSD17B2 | HSD17B3 1/4885NOTUM 907/4885CYP11B1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.